GEMPHARMATECH CO., LTD.

BiocytogenBiotechUnited States

77% match

Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.

フェニックスバイオ6190 · BiotechHigashihiroshima, Japan

71% matchPublic

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.

SHANGHAI OPM BIOSCIENCES CO., LTD.688293 · BiotechnologyChina

68% matchPublic

Shanghai OPM Biosciences Co., Ltd. provides high-performance cell culture media, custom media development, and end-to-end CRDMO and CRO services for biopharmaceutical and biologics companies. Its offerings support clients across the drug R&D lifecycle, from early discovery and cell line development through clinical and commercial manufacturing.

GenoskinBiotechFrance

68% match

Genoskin provides ex vivo human skin models, primary human mast cells, and contract research services designed to replace animal testing and improve non-clinical drug development. The company serves pharmaceutical, biotechnology, cosmetics, medical device, and academic research organizations by delivering human-relevant data for safety, efficacy, toxicology, and disease research.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

トランスジェニックグループ2342 · BiotechFukuoka City, Japan

67% matchPublic

Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilation of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.